112 related articles for article (PubMed ID: 19844954)
1. Effect of O6-chloroethylguanine DNA lesions on the kinetics and mechanism of micronucleus induction in vivo.
Morales-Ramírez P; Vallarino-Kelly T; Cruz-Vallejo VL
Environ Mol Mutagen; 2010 Apr; 51(3):236-42. PubMed ID: 19844954
[TBL] [Abstract][Full Text] [Related]
2. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
4. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity.
Harris LC; Marathi UK; Edwards CC; Houghton PJ; Srivastava DK; Vanin EF; Sorrentino BP; Brent TP
Clin Cancer Res; 1995 Nov; 1(11):1359-68. PubMed ID: 9815932
[TBL] [Abstract][Full Text] [Related]
5. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model.
Guarnieri M; Biser-Rohrbaugh A; Tyler BM; Gabikian P; Bunton TE; Wu QZ; Weingart J; Carson BS
Cancer Chemother Pharmacol; 2002 Nov; 50(5):392-6. PubMed ID: 12439597
[TBL] [Abstract][Full Text] [Related]
7. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
8. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
[TBL] [Abstract][Full Text] [Related]
9. O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells.
Westerhof GR; Down JD; Blokland I; Wood M; Boudewijn A; Watson AJ; McGown AT; Ploemacher RE; Margison GP
Exp Hematol; 2001 May; 29(5):633-8. PubMed ID: 11376877
[TBL] [Abstract][Full Text] [Related]
10. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA.
Maze R; Kapur R; Kelley MR; Hansen WK; Oh SY; Williams DA
J Immunol; 1997 Jan; 158(2):1006-13. PubMed ID: 8993023
[TBL] [Abstract][Full Text] [Related]
11. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
Marathi UK; Dolan ME; Erickson LC
Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
[TBL] [Abstract][Full Text] [Related]
12. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.
Hansen RJ; Nagasubramanian R; Delaney SM; Samson LD; Dolan ME
Carcinogenesis; 2007 May; 28(5):1111-6. PubMed ID: 17116724
[TBL] [Abstract][Full Text] [Related]
13. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
14. Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
Gerson SL; Phillips W; Kastan M; Dumenco LL; Donovan C
Blood; 1996 Sep; 88(5):1649-55. PubMed ID: 8781420
[TBL] [Abstract][Full Text] [Related]
15. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
[TBL] [Abstract][Full Text] [Related]
16. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
18. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
19. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
Adams DM; Zhou T; Berg SL; Bernstein M; Neville K; Blaney SM;
Pediatr Blood Cancer; 2008 Mar; 50(3):549-53. PubMed ID: 17941066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
